| Released | Contributor | Author | Title | Pages | Price |
|---|
| Jun 18, 2013 | New Constructs, LLC | N/A | REGN: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | Jun 18, 2013 | Stock Traders Daily | Thomas H Kee Jr. | Trading Report for (REGN). A detailed report, including free correlated market analysis, and updates. | 5 | $57.50 | | Jun 18, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical-biomed/genetics | 18 | $207 | | Jun 17, 2013 | Stock Traders Daily | Thomas H Kee Jr. | The Investment Rate - a measure of investment demand. | 43 | $494.50 | | Jun 17, 2013 | Alpha Street Research | Hunter Orr | REGN - Regeneron Pharmaceuticals Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report | 9 | $24 | | Jun 16, 2013 | Pechala's Reports | Lubomir Pechala | REGENERON PHARMACEUTICALS INC (REGN) - REPORT FOR ACTIVE TRADERS | 1 | $25 | | Jun 16, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 | | Jun 14, 2013 | S&P Capital IQ – STARS Reports | N/A | Regeneron Pharmaceuticals | 10 | $115 | | Jun 14, 2013 | Pechala's Reports | Frantisek Pechala | REGENERON PHARMACEUTICALS INC (REGN) 12-months forecast | 1 | $15 | | Jun 13, 2013 | Wright Reports | N/A | Wright Industry Averages: Pharmaceuticals & Biotechnology (United States) | 77 | $885.50 |
|
View All Reports for REGN ... |
|
|
10.93(4.50%) 3:56PM EDT - Nasdaq Real Time Price